Kan det være han planlegger å kaste ledelsen?
Godt mulig han kan også satse på neste store trigger for PHO, fase 3 resultat fleksibelt scope som er meget sannsynlig blir bra.
26/04-2017 08:12:15: (PHO) Photocure ASA: Late-Breaking Plenary Presentation at the AUA 2017 Annual Meeting on Blue Light Flexible Cystoscopy with Hexaminolevinulate Phase 3 Study
Data on US Registry Study for BLC™ with Cysview/Hexvix will also be Presented at AUA
Oslo, Norway, April 26, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that results from the BLFC with Cysview®/Hexvix® Phase 3 study will be presented during a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting in Boston, Mass., May 12-16, 2017.
The late-breaking presentation will report results from a prospective multi-center study, carried out at 17 centers in the United States (US), on detection and impact on patient management of Cysview in patients with non-muscle invasive bladder cancer undergoing surveillance with a flexible cystoscopy to detect the recurrence of bladder cancer.
New data will also be presented at AUA on a prospective multicenter registry that has been established to study the use of BLC™ (Blue Light Cystoscopy) with Cysview in the operating room setting. This registry, which is the largest non-muscle invasive bladder cancer registry in the US, continues to add to the growing body of evidence of how BLC with Cysview can improve the detection and management of bladder cancer in various patient populations.
http://www.netfonds.no/quotes/release.php?id=20170426.GlobeNewswire.HUG2098610
Børsen overhodet ikke på ballen. Jeg kjøper en lyttepost i morgen!
kursen har begynt å røre litt på seg, men ja, dette er et viktig resultat som kommer fra PHO her og det kan være en betydelig trigger med høy sannsynlighet for godkjennelse statistisk sett for fase 3. enda høyere blir LOA pga PHO har allerede fått det til for rigid scope, nå gjenstår flexible scope som åpner opp dørene for et mye større marked.
Hmm, er jo teknisk litt uavklart om den skal stige videre… Visste ikke at den hadde duppet SÅ ille.
1 Like
Føler fortsatt PHO lider under hasse rabatten.
1 Like
Gikk inn med en mindre post enn jeg hadde tenk i utganspunktet da jeg så late breaker, fordi det ser ut som om den kan dippe litt.
Men jeg synes aksjen fremstår temmelig billig ift potensialet.
Pen recovery tilbake til SMA50!
Vi nærmer oss Fase 3 data.
Oslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today
announced the appointment of Jeremy Bahr as Chief Business
Officer.
“I am pleased to welcome Jeremy to the Photocure team,
strengthening our strategic, commercial and transactional
capabilities, where he will lead our business development
activities and strategic initiatives within marketing and
market access. Jeremy joins Photocure as Chief Business
Officer with over 20 years of professional experience and I
look forward to working with him as a member of the Photocure
management team,” says Kjetil Hestdal, President and Chief
Executive Officer of Photocure.
Bahr comes from UCB, where his most recent role was Global
Head of Market Analytics at UCB, and where he also previously
served as Head of Commercial Operations in North America.
Prior to UCB, he spent 7 years at Pfizer where he held senior
roles within strategy, sales and marketing. Earlier in his
career he worked in private equity, as an entrepreneur and
spent several years as a consultant at McKinsey & Company.
Jeremy Bahr holds an MBA from Harvard Business School, and
bachelor’s degrees in Molecular Biology and Political Science
from Brigham Young University.
http://www.netfonds.no/quotes/release.php?id=20170505.OBI.20170505S15
Jeg synes meldingen over er interessant. Det kan tyde på at ny styreformann har tatt grep og at Hestdal får litt hjelp der han nok er svakest. Det er nok få som blir veldig lei seg den dagen Hestdal slutter.
dettte kunne ha blitt en god pho dag, men dessverre bare måtte BER selge 39k aksjer og omtrent på egen hånd dumpe kursen fra ca 36 til 33.gŕŕrrrrrrrr.
JADA, sjekk den p-verdien!
Oslo, Norway, May 12th, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that a Phase 3 trial investigating Blue Light Flexible Cystoscopy (BLFC™) with Cysview®/Hexvix® in the surveillance setting met the study primary end point. Results from the study showed a highly statistically significant improvement (p <0.0001) in the detection of patients with recurrence of bladder cancer using BLFC with Cysview compared to white light (WL) alone in patients with non-muscle invasive bladder cancer (NMIBC) undergoing surveillance cystoscopy. Detailed data from the study will be presented during a late-breaking plenary abstract session on May 14th at the American Urological Association, 2017 meeting.
“We are very pleased with the strong results of this Phase 3 study and we appreciate the work from investigators and patients who participated in the study. There are approximately 1.4 million surveillance cystoscopies performed in the US annually. These results represent an important milestone for the potential improvement in the management of patients. Later this year we intend to submit the data to the US Food and Drug Administration (FDA) to seek a label expansion for the indication of BLFC with Cysview in the surveillance setting.” said Kjetil Hestdal, M.D., Ph.D., President and CEO, Photocure ASA."
The Phase 3 study was a prospective, open, comparative, within-patient controlled study, including 304 patients enrolled at 17 academic institutions in the US.
http://www.netfonds.no/quotes/release.php?id=20170512.GlobeNewswire.HUG2103582
1 Like
Jeg skjønner absolutt ingenting av den siste dippen, var jo penger på gata.
Sikkert et fond som skulle redusere/ut.Så det samme i PCIB.
Jo men rett før late breaking av fase 3? Weird.
1 Like
Ja helt uforståelig, salget så jo ut som om noen satte en short like før fase-3 resultat og late breaking og det er noe man vil tape på i lengden.
Er jo bare å ta av seg hatten og gratulere dei som kjøpte på duppen PHO hadde, nese for peng, eg hadde ikke det
1 Like
Jeg solgte på dippen 
Kan noen forklare litt hva dette vil bety for selskapet?
Det gjelder vel eksisterende produkt som allerede selges (Cysview/Hexvix), Så er tanken at dette vil gi en boost til salget?